| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | — | — |
| R&D Expense | $17.9M | — | — |
| SG&A Expense | $7.9M | — | +229.9% |
| Operating Income | -$24.7M | — | -930.9% |
| Income Tax | $0 | — | — |
| Net Income | -$23.3M | +0.1% | -893.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $189.2M | -11.3% | +3269.4% |
| Accounts Receivable | $0 | -100.0% | — |
| Current Assets | $195.6M | -17.4% | +3163.6% |
| Total Assets | $199.1M | -17.1% | +3223.2% |
| Current Liabilities | $14.2M | -60.7% | +442.4% |
| Total Liabilities | $15.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.9M | — | -75.0% |
| Capital Expenditures | $147K | — | — |
| Investing Cash Flow | -$8.1M | — | — |
| Financing Cash Flow | -$6.9M | — | -367.4% |
| Free Cash Flow | -$9.1M | — | -77.9% |
| +484.0% |
| Stockholders' Equity | $183.8M | -9.4% | +5346.9% |